Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2006

Open Access 01-12-2006 | Research

Overexpression of Eag1 potassium channels in clinical tumours

Authors: Bernhard Hemmerlein, Rüdiger M Weseloh, Fernanda Mello de Queiroz, Hendrik Knötgen, Araceli Sánchez, María E Rubio, Sabine Martin, Tessa Schliephacke, Marc Jenke, Heinz-Joachim-Radzun, Walter Stühmer, Luis A Pardo

Published in: Molecular Cancer | Issue 1/2006

Login to get access

Abstract

Background

Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques.

Results

The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA).

Conclusion

Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.
Appendix
Available only for authorised users
Literature
1.
Hille B: Ion channels of excitable membranes, Third Edition. 2001, Sunderland, Massachussets , Sinauer Associates Inc..
2.
Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stuhmer W: Role of voltage-gated potassium channels in cancer. J Membr Biol. 2005, 205 (3): 115-124. 10.1007/s00232-005-0776-1CrossRefPubMed
3.
Pardo LA: Voltage-gated Potassium Channels in Cell Proliferation. Physiology. 2004, 19: 285-292. 10.1152/physiol.00011.2004CrossRefPubMed
4.
Stühmer W, Alves F, Hartung F, Zientkowska M, Pardo LA: Potassium channels as tumour markers. FEBS Lett. 2006, 580 (12): 2850-2852. 10.1016/j.febslet.2006.03.062CrossRefPubMed
5.
Conti M: Targeting K+ channels for cancer therapy. J Exp Ther Oncol. 2004, 4: 161-166.PubMed
6.
Pardo LA, del Camino D, Sánchez A, Alves F, Brüggemann A, Beckh S, Stühmer W: Oncogenic potential of EAG K+ channels. EMBO J. 1999, 18 (20): 5540-5547. 10.1093/emboj/18.20.5540PubMedCentralCrossRefPubMed
7.
Camacho J, Sánchez A, Stühmer W, Pardo LA: Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflugers Archiv Eur J Physiol. 2000, 441 (2-3): 167-174. 10.1007/s004240000420CrossRef
8.
Pardo LA, Brüggemann A, Camacho J, Stühmer W: Cell cycle-related changes in the conducting properties of r-eag K+ channels. J Cell Biol. 1998, 143 (3): 767-775. 10.1083/jcb.143.3.767PubMedCentralCrossRefPubMed
9.
Brüggemann A, Stühmer W, Pardo LA: Mitosis-promoting factor-mediated suppression of a cloned delayed rectifier potassium channel expressed in Xenopus oocytes. Proc Natl Acad Sci USA. 1997, 94 (2): 537-542. 10.1073/pnas.94.2.537PubMedCentralCrossRefPubMed
10.
Bijlenga P, Occhiodoro T, Liu JH, Bader CR, Bernheim L, Fischerlougheed J: An ether-a-go-go K+ current, ih-eag, contributes to the hyperpolarization of human fusion-competent myoblasts. J Physiology. 1998, 512 (2): 317-323. 10.1111/j.1469-7793.1998.317be.x.CrossRef
11.
Occhiodoro T, Bernheim L, Liu JH, Bijlenga P, Sinnreich M, Bader CR, Fischer-Lougheed J: Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion. FEBS Lett. 1998, 434 (1-2): 177-182. 10.1016/S0014-5793(98)00973-9CrossRefPubMed
12.
13.
Meyer R, Schonherr R, Gavrilova-Ruch O, Wohlrab W, Heinemann SH: Identification of ether a go-go and calcium-activated potassium channels in human melanoma cells. J Memb Biol. 1999, 171 (2): 107-115. 10.1007/s002329900563CrossRef
14.
Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, Prevarskaya N: Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: Possible involvement of a h-ether.a-gogo K+ channel. Recept Channels. 2001, 7 (5): 345-356.PubMed
15.
Weber C, Mello de Queiroz F, Downie B, Sukow A, Stühmer W, Pardo LA: Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNAi. J Biol Chem. 2006, 281: 13033-13037. 10.1074/jbc.M600883200.CrossRef
16.
Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, Wohlrab W, Heinemann SH: Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Memb Biol. 2002, 188 (2): 137-149. 10.1007/s00232-001-0181-3CrossRef
17.
Mello de Queiroz F, Suarez-Kurtz G, Stühmer W, Pardo LA: Ether à go-go Potassium Channel Expression in Soft Tissue Sarcoma Patients. Mol Cancer. 2006, 5: 42- 10.1186/1476-4598-5-42PubMedCentralCrossRefPubMed
18.
Farias LMB, Bermúdez Ocaña D, Díaz L, Larrea F, Avila-Chávez E, Cadena A, Hinojosa LM, Lara G, Villanueva LA, Vargas C, Hernández-Gallegos E, Camacho-Arroyo I, Dueñas-González A, Pérez-Cárdenas E, Pardo LA, Morales A, Taja-Chayeb L, Escamilla J, Sánchez-Peña C, Camacho J: Ether à go-go Potassium Channels as Human Cervical Cancer Markers. Cancer Res. 2004, 64: 6996-7001. 10.1158/0008-5472.CAN-04-1204CrossRefPubMed
19.
Saganich MJ, de Miera EVS, Nadal MS, Baker H, Coetzee WA, Rudy B: Cloning of components of a novel subthreshold-activating K+ channel with a unique pattern of expression in the cerebral cortex. J Neurosci. 1999, 19 (24): 10789-10802.PubMed
20.
Ludwig J, Weseloh R, Karschin C, Liu Q, Netzer R, Engeland B, Stansfeld C, Pongs O: Cloning and functional expression of rat eag2, a new member of the ether-a-go-go family of potassium channels and comparison of its distribution with that of eag1. Mol Cell Neurosci. 2000, 16 (1): 59-70. 10.1006/mcne.2000.0851CrossRefPubMed
21.
Ju M, Wray D: Molecular identification and characterisation of the human eag2 potassium channel. FEBS Lett. 2002, 524 (1-3): 204-210. 10.1016/S0014-5793(02)03055-7CrossRefPubMed
22.
Jenke M, Sánchez A, Monje F, Stühmer W, Weseloh RM, Pardo LA: C-terminal domains implicated in the functional surface expression of potassium channels. EMBO J. 2003, 22 (3): 395-403. 10.1093/emboj/cdg035PubMedCentralCrossRefPubMed
23.
García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA: Mechanism of Block of hEag1 K+ Channels by Imipramine and Astemizole. J Gen Physiol. 2004, 124: 301-317. 10.1085/jgp.200409041PubMedCentralCrossRefPubMed
24.
Napp J, Monje F, Stühmer W, Pardo LA: Glycosylation of Eag1 (Kv10.1) potassium channels: intracellular trafficking and functional consequences. J Biol Chem. 2005, 280 (33): 29506-29512. 10.1074/jbc.M504228200CrossRefPubMed
25.
Petralia RS, Rubio ME, Wenthold RJ: Cellular and subcellular distribution of glutamate receptors. Ionotropic Glutamate Receptors In The CNS. 1999, 141: 143-171.CrossRef
26.
Saganich MJ, Machado E, Rudy B: Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci. 2001, 21 (13): 4609-4624.PubMed
27.
Jeng CJ, Chang CC, Tang CY: Differential localization of rat Eag1 and Eag2 K+ channels in hippocampal neurons. Neuroreport. 2005, 16 (3): 229-233. 10.1097/00001756-200502280-00005CrossRefPubMed
28.
Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988, 85: 5879-5883. 10.1073/pnas.85.16.5879PubMedCentralCrossRefPubMed
29.
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M: Single-chain antigen-binding proteins. Science. 1988, 242: 423-426. 10.1126/science.3140379CrossRefPubMed
30.
Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E, Oppermann H: Protein engineering of single-chain Fv analogs and fusion proteins. Meth Enzymol. 1991, 203: 46-88.CrossRefPubMed
31.
Kurucz I, Jost CR, George AJ, Andrew SM, Segal DM: A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor. Proc Natl Acad Sci U S A. 1993, 90: 3830-3834. 10.1073/pnas.90.9.3830PubMedCentralCrossRefPubMed
32.
Matlin AR, Kendall DA, Carano KS, Banzon JA, Klecka SB, Solomon NM: Enhanced catalysis by active-site mutagenesis at aspartic acid 153 in Escherichia coli alkaline phosphatase. Biochemistry. 1992, 31: 8196-8200. 10.1021/bi00150a011CrossRefPubMed
33.
Schonherr R: Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol. 2005, 205 (3): 175-184. 10.1007/s00232-005-0782-3CrossRefPubMed
34.
35.
Patt S, Preussat K, Beetz C, Kraft R, Schrey M, Kalff R, Schonherr K, Heinemann SH: Expression of ether a go-go potassium channels in human gliomas. Neurosci Lett. 2004, 368 (3): 249-253. 10.1016/j.neulet.2004.07.001CrossRefPubMed
36.
Warmke JW, Ganetzki B: A family of potassium channel genes related to eag in drosophila and mammals. Proc Natl Acad Sci USA. 1994, 91: 3438-3442. 10.1073/pnas.91.8.3438PubMedCentralCrossRefPubMed
37.
Bianchi L, Wible B, Arcangeli A, Taglialatela M, Morra F, Castaldo P, Crociani O, Rosati B, Faravelli L, Olivotto M, Wanke E: HERG encodes a K+ current highly conserved in tumors of different histogenesis - a selective advantage for cancer cells?. Cancer Res. 1998, 58 (4): 815-822.PubMed
38.
Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, Noci I, Borri P, Borrani E, Giachi M, Becchetti A, Rosati B, Wanke E, Olivotto M, Arcangeli A: HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Brit J Cancer. 2000, 83 (12): 1722-1729. 10.1054/bjoc.2000.1497PubMedCentralCrossRefPubMed
39.
Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, Schlichter LC: Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem. 2002, 277 (21): 18528-18534. 10.1074/jbc.M200592200CrossRefPubMed
40.
Suzuki T, Takimoto K: Selective expression of HERG and Kv2 channels influences proliferation of uterine cancer cells. Int J Oncol. 2004, 25 (1): 153-159.PubMed
41.
Cayabyab FS, Schlichter LC: Regulation of an ERG K+ current by Src tyrosine kinase. Journal of Biological Chemistry. 2002, 277 (16): 13673-13681. 10.1074/jbc.M108211200CrossRefPubMed
42.
Shoeb F, Malykhina AP, Akbarali HI: Cloning and functional characterization of the smooth muscle ether-a-go-go-related gene K+ channel. Potential role of a conserved amino acid substitution in the S4 region. J Biol Chem. 2003, 278 (4): 2503-2514. 10.1074/jbc.M208525200CrossRefPubMed
43.
Bast RCJ, Ravdin P, Hayes DF, Bates S, Fritsche HJ, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR: 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001, 19 (6): 1865-1878.PubMed
44.
Wang RF: Human tumor antigens: implications for cancer vaccine development. J Mol Med. 1999, 77 (9): 640-655. 10.1007/s001099900042CrossRefPubMed
45.
46.
Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer. 1990, 45 (3): 457-461.CrossRefPubMed
47.
Mènard S, Tagliabue E, Campiglio M, Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000, 182: 150-162. 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-ECrossRefPubMed
48.
Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001, 7 (5): 548 -5552. 10.1038/87872CrossRefPubMed
49.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Süto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after Adjuvant Chemotherapyin HER2-Positive Breast Cancer. NEJM. 2005, 353: 1659-1672. 10.1056/NEJMoa052306CrossRefPubMed
50.
Krieg PA, Melton DA: In vitro RNA synthesis with SP6 RNA polymerase. Meth Enzymol. 1987, 155: 397-415.CrossRefPubMed
51.
Karlsson R, Michaelsson A, Mattsson L: Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Meth. 1991, 145 (1-2): 229-240. 10.1016/0022-1759(91)90331-9CrossRef
52.
Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: Sequences of proteins of immunogical interes NIH publication No. 91-3242. 1991, Bethesda, MD , US department of Health and Human Services, Public Health Service, National Institutes of Health, 5.
53.
Watson PH, Snell L, Parisien M: The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ. 1996, 155: 281-283.PubMedCentralPubMed
Metadata
Title
Overexpression of Eag1 potassium channels in clinical tumours
Authors
Bernhard Hemmerlein
Rüdiger M Weseloh
Fernanda Mello de Queiroz
Hendrik Knötgen
Araceli Sánchez
María E Rubio
Sabine Martin
Tessa Schliephacke
Marc Jenke
Heinz-Joachim-Radzun
Walter Stühmer
Luis A Pardo
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2006
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-5-41

Other articles of this Issue 1/2006

Molecular Cancer 1/2006 Go to the issue

Research

Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B

Research

Dominant negative retinoic acid receptor initiates tumor formation in mice

Review

Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review

Research

Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors

Research

Ether à go-go potassium channel expression in soft tissue sarcoma patients

Research

Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits